The Threat of Bioterrorism in America: Assessing the Adequacy of the Federal Law Relating to Dangerous Biological Agents : Hearing Before the Subcommittee on Oversight and Investigations of the Committee on Commerce, House of Representatives, One Hundred Sixth Congress, First Session, May 20, 1999, 4. sējumsU.S. Government Printing Office, 1999 - 70 lappuses |
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
agency anthrax appropriate ATLAS background checks balance BILBRAY biological terrorism biological weapons Biological Weapons Convention biomedical biosafety biosafety level bioterrorism bioterrorist botulism BURNHAM BURR CDC's Centers for Disease Chairman clinical committee concern Congress CONNELL crime bill criminal develop diagnostic Disease Control effective ensure Federal FedEx GANSKE GENE GREEN handling Health and Human health and safety Human Services individuals infectious agents infectious diseases inspection institutions involved issues laboratory labs Lavy law enforcement legislation legitimate listed agents MARKEY ment microbiology nuclear Okay OSTROFF package pathogens potential PREPARED STATEMENT PRESLAR proposal public health purposes question RAUB registered facility regulations regulatory require responsibility REYNOLDS ricin scientists select agent list select agents shipment special biological agents statutes STUPAK subcommittee terrorists testimony Thank threat of bioterrorism tion toxins transfer of select UPTON weapons of mass Yersinia pestis
Populāri fragmenti
25. lappuse - Registration of Facilities Handling Select Agents Commercial suppliers of select agents, as well as government agencies, univer-sities, research institutes and private companies that seek to transfer or receive these agents, are required to register with CDC and obtain a unique site registration number. The registration process requires that a responsible facility official certify that the facility and its laboratories meet the Biosafety Level 2, 3, and/or 4 standards for working with dangerous pathogens...
26. lappuse - As the nation's disease prevention and control agency, it is CDC's responsibility on behalf of DHHS to provide national leadership in the public health and medical communities in a concerted effort to detect, diagnose, respond to, and prevent illnesses, including those that occur as a result of a deliberate release of biological agents.
14. lappuse - Whoever knowingly develops, produces, stockpiles, transfers, acquires, retains, or possesses any biological agent, toxin, or delivery system for use as a weapon, or knowingly assists a foreign state or any organization to do so, shall be fined under this title or imprisoned for life or any term of years, or both.
48. lappuse - Stroke is the third leading cause of death in the United States and the leading cause of disability among adults.
26. lappuse - Licensed vaccines containing less pathogenic strains of some of the select viral and bacterial agents are exempted from the list of agents. Transport of clinical specimens for diagnostic and verification purposes are also exempt, as are certain toxins used for legitimate medical purposes or biomedical research.
27. lappuse - ... infrastructure and training; and disease prevention and control. This plan emphasizes the need to be prepared for the unexpected — whether it be a naturally occurring influenza pandemic or the deliberate release of anthrax by a terrorist.
24. lappuse - Counselors for the National Center for Infectious Diseases at the Centers for Disease Control and Prevention, and she chairs the Institute of Medicine's Clinical Research Roundtable.
69. lappuse - PhRMA companies are leading the way in the search for new cures and treatments. Currently, there are 136 new medicines in development to treat or prevent infectious diseases, humankind's oldest and most persistent enemy.
1. lappuse - THE DEPARTMENT OF ENERGY'S NUCLEAR WEAPON LABORATORIES TUESDAY, OCTOBER 26, 1999 HOUSE OF REPRESENTATIVES, COMMITTEE ON COMMERCE, SUBCOMMITTEE ON OVERSIGHT AND INVESTIGATIONS, Washington, DC. The subcommittee met, pursuant to notice, at 10:05 am, in room 2322, Rayburn House Office Building, Hon.
24. lappuse - Science, National Center for Infectious Diseases at the Centers for Disease Control and Prevention. I am pleased to be here to describe CDC's role in regulating the shipment of select agents that are capable of causing substantial harm to human health. In addition, the Committee asked CDC to address the adequacy and effectiveness of other safeguards to prevent using biologic agents to harm the public health.